Evolution of prostate cancer treatment gathers speed
What are the treatment options for this too-prevalent disease? And the outlook for the future as clinical outcomes evolve?
Recent data show that prostate cancer is the second most common cancer diagnosis amongst men globally, and one of the leading causes of cancer deaths. So what are the treatment options for this too-prevalent disease? And the outlook for the future as clinical outcomes evolve? Amy Butcher from Ipsos’ Global Oncology Monitor team explores currently available treatments and those in the pipeline, concluding that the evolution of prostate cancer treatment is gathering speed, offering new hopes for patients affected by this disease.
Read the full article on Pharmaceutical Executive.
